Literature DB >> 10713338

Allergen-specific IgE levels against crude mould and storage mite extracts and recombinant mould allergens in sera from horses affected with chronic bronchitis.

C Eder1, R Crameri, C Mayer, R Eicher, R Straub, H Gerber, S Lazary, E Marti.   

Abstract

Immunoglobulin E antibody (IgE) levels against four recombinant (r) mould allergens (r-Aspergillus fumigatus [rAsp f] 7, 8 and 9; r-Alternaria alternata 1 [rAlta1]) and crude mould (Aspergillus fumigatus, Alternaria alternata, Penicillium notatum) and storage mite extracts were determined by ELISA in sera from 24 pulmonary sound control horses and 26 horses suffering from chronic bronchitis/bronchiolitis (CB), also called chronic obstructive pulmonary disease (COPD). Serum IgG and IgA titres were also determined against Aspergillus fumigatus extract and rAsp f 8.IgE against the crude extracts could be measured in all sera, but there was no significant difference between CB-affected and control horses. In contrast, only 8-30% of the horses, depending on the r-allergen tested, had detectable IgE levels in serum against the r-allergens. Horses with CB had significantly more often detectable IgE levels than controls against rAlt a 1 (10/26 and 3/24, respectively, p=0. 054), rAsp f 7 (13/26 and 2/24, respectively, p<0.01) and rAsp f 8 (11/26 and 1/24, respectively, p<0.01). Only four horses (three CB-affected and one healthy, p0.05) had detectable IgE levels against rAsp f 9. Furthermore, CB-affected horses were often sensitised against two or more r-allergens (13/26 of the CB-affected horses) while only one of the 24 healthy horses had positive IgE levels against more than one r-allergens. Similarly to IgE levels, no significant differences between CB-affected and healthy horses were found for IgG titres against the Aspergillus fumigatus extract. However, horses with CB had significantly higher serum IgG titres against rAsp f 8 than healthy controls (median=28 versus 10 relative ELISA units [REU], p<0.01). Additionally, horses with detectable IgE titres against rAsp f 8 had significantly higher IgG titres against this r-allergen than horses with undetectable IgE titres (median IgG titres=46 and 13 REU, respectively; p<0.01). For serum IgA titres, neither differences between healthy and CB-affected animals nor correlations between IgA and IgG or IgE titres could be found. These results show that horses suffering from CB are more often sensitised to some Aspergillus fumigatus and Alternaria alternata allergens than control horses and that they are partly sensitised to the same fungal proteins as mould-allergic human patients. Furthermore, this study shows that r-allergens allow a much more sensitive determination of specific serum antibody levels by ELISA than crude mould extracts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713338     DOI: 10.1016/s0165-2427(00)00154-9

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  16 in total

1.  Detection of reaginic antibodies against Faenia rectivirgula from the serum of horses affected with Recurrent Airway Obstruction by an in vitro bioassay.

Authors:  Gabriel Morán; Hugo Folch; Oscar Araya; Rafael Burgos; Miguel Barria
Journal:  Vet Res Commun       Date:  2010-09-03       Impact factor: 2.459

2.  Reaginic antibodies from horses with recurrent airway obstruction produce mast cell stimulation.

Authors:  G Moran; H Folch; C Henriquez; A Ortloff; M Barria
Journal:  Vet Res Commun       Date:  2012-08-12       Impact factor: 2.459

3.  Increased apoptosis of CD4 and CD8 T lymphocytes in the airways of horses with recurrent airway obstruction.

Authors:  Gabriel Moran; Virginia A Buechner-Maxwell; Hugo Folch; Claudio Henriquez; Juan S Galecio; Barbara Perez; Cristian Carrasco; Miguel Barria
Journal:  Vet Res Commun       Date:  2011-05-19       Impact factor: 2.459

4.  The Hygienic Status of Different Forage Types for Horses-A Retrospective Study on Influencing Factors and Associations with Anamnestic Reports.

Authors:  Sandra Intemann; Bernd Reckels; Dana Schubert; Petra Wolf; Josef Kamphues; Christian Visscher
Journal:  Vet Sci       Date:  2022-05-06

5.  Characterization of fungal exposure and dectin-1 expression in healthy horses and horses with severe asthma.

Authors:  Rebecca Di Pietro; Valérie Dubuc; Estelle Manguin; Roxane Giroux-Lafond; Christian Bédard; Roxane Boivin; Jean-Pierre Lavoie; Stephen J Vesper; Mathilde Leclere
Journal:  Am J Vet Res       Date:  2022-05-08       Impact factor: 1.055

6.  In vitro bioassay to detect reaginic antibodies from the serum of horses affected with recurrent airway obstruction.

Authors:  Gabriel Morán; Rafael Burgos; Oscar Araya; Hugo Folch
Journal:  Vet Res Commun       Date:  2009-12-10       Impact factor: 2.459

7.  A whole-genome scan for recurrent airway obstruction in Warmblood sport horses indicates two positional candidate regions.

Authors:  June E Swinburne; Helen Bogle; Jolanta Klukowska-Rötzler; Michaela Drögemüller; Tosso Leeb; Elizabeth Temperton; Gaudenz Dolf; Vincent Gerber
Journal:  Mamm Genome       Date:  2009-08       Impact factor: 2.957

8.  Identification, expression and characterisation of a major salivary allergen (Cul s 1) of the biting midge Culicoides sonorensis relevant for summer eczema in horses.

Authors:  Kathrin F A Langner; Donald L Jarvis; Manfred Nimtz; Julia E Heselhaus; Linda E McHolland; Wolfgang Leibold; Barbara S Drolet
Journal:  Int J Parasitol       Date:  2008-07-26       Impact factor: 3.981

9.  Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid.

Authors:  J Sarmiento; B Perez; N Morales; C Henriquez; L Vidal; H Folch; J S Galecio; G Morán
Journal:  Vet Res Commun       Date:  2013-07-12       Impact factor: 2.459

10.  Comparison of genomic and proteomic data in recurrent airway obstruction affected horses using Ingenuity Pathway Analysis®.

Authors:  Julien Racine; Vinzenz Gerber; Marybeth Miskovic Feutz; C Paige Riley; Jiri Adamec; June E Swinburne; Laurent L Couetil
Journal:  BMC Vet Res       Date:  2011-08-15       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.